Pubdate: Thu, 08 Mar 2001 Source: Guardian Weekly, The (UK) Section: Page 1 Copyright: Guardian Publications 2001 Contact: 75 Farringdon Road London U.K EC1M 3HQ Fax: 44-171-242-0985 Website: http://www.guardianunlimited.co.uk/GWeekly/front/ Author: Chris McGreal in Pretoria SOUTH AFRICA'S SICK AWAIT JUDGMENT DAY Multinationals Go To Court Over A Law Aimed At Cutting The Cost Of Medicines The world's largest pharmaceutical companies opened their lawsuit against the South African government's attempt to import cheaper anti-Aids drugs and other medicines on Monday by claiming that property rights were the central issue of the case. But demonstrators outside Pretoria high court and across the globe said that what was really at stake was millions of lives of Aids sufferers. Nearly 40 pharmaceutical companies claim that a new law which will permit the importation of generic drugs and patented medicines from suppliers at prices lower than those of the main drug giants breaches South Africa's constitution and international trade agreements. The South African government argues that it has the right to put the lives of the poor ahead of multinationals' profits. The outcome of the lawsuit could have important implications for access to cheaper medicines to fight Aids and other devastating diseases across the developing world. The court's ruling will also have a significant impact on health care in South Africa, where nearly half of all health spending goes to pay for drugs, compared with less than 15% in Britain's national health service. The pharmaceutical companies want the high court to strike down a law that permits the South African government to buy patented drugs from suppliers other than the manufacturer, or generic drugs from factories in India or Brazil, when patented medicines are "unaffordable" or there is a "health emergency" such as Aids. The legislation also bans the practice of paying incentives to doctors to prescribe expensive brand name medicines. The drug firms say they are not trying to justify unethical and protectionist practices but to defend their patents and to strike down a law they say is unconstitutional in part because it lacks clarity on issues such as what is "unaffordable". But the director general of South Africa's health ministry, Ayanda Ntsaluba, accuses pharmaceutical companies of opposing ethical laws that are standard practice in Western countries. "This case is about how we get affordable drugs to the majority of people in South Africa. There are drugs that we pay more for here than they do in Europe," he said. "It's also about how you prescribe and distribute those drugs. There are some very dubious practices and we want to put a stop to them. The drug companies oppose us and we've told them that the things they don't want us to stop in our own society would never be permitted in their own." The Pharmaceutical Manufacturers' Association (PMA), representing 39 big drug companies, won a court injunction blocking the law's implementation three years ago by claiming that it breached international trade agreements, specifically the Trade Related Intellectual Property Rights (Trips), by in effect scrapping recognition of patents on medicines. The Clinton administration backed the drug companies and put South Africa on a "watch list" of nations declared patent pirates. But over time the South African govern ment made a persuasive case that the law is permitted under Trips, and South Africa was dropped from the watch list. The Bush administration has gone further, and said it does not oppose the new legislation. The drug companies have also been isolated by other foreign governments. On top of that the European Union and the World Health Organisation say they do not oppose South Africa's right to implement the new legislation. The World Trade Organisation has said that the laws do not infringe international patent protections. On Monday protesters rallied against the drug companies across South Africa and in other countries, including Australia, Canada, France, Germany, Britain and the United States. The leadership of South Africa's powerful trade union confederation, Cosatu, led a march of several thousand people to the US embassy in Pretoria. However, the head of the PMA, Mirryena Deeb, said: "There is lack of due process. The minister can make a decision that a drug is too expensive and the drug companies have no right to defend themselves. This law is arbitrary and gives the health minister too many powers . . . The state cannot know what it costs to treat HIV-positive people because it has never asked us. Three years ago GlaxoWellcome [which merged with SmithKline Beecham last year to form GlaxoSmithKline] approached them and offered a world best price. The government said it was too expensive. Glaxo said: 'Tell us what you can afford.' The government never came back." But Dr Ntsaluba argues that, even with the discounts offered to other governments, his own could not afford to buy many brand-name drugs, particularly those used for treating HIV. The government has pointed out that drugs such as the antibiotic Ciprofloxican, considered an "essential medicine", cost South Africa's public health sector 75 cents for each pill, and the country's private health care providers more than $4.50 a tablet. If the new law is implemented, a generic of the drug could be imported from India for just 6c a pill. If the legislation comes into force, it will have a big impact on the treatment of South Africa's 4m people with HIV - about 10% of the population - and other serious diseases. - --- MAP posted-by: Beth